Cargando…

MLTI-02. A PHASE I TRIAL OF SORAFENIB WITH WHOLE BRAIN RADIOTHERAPY (WBRT) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES AND A CORRELATIVE FLT-PET BRAIN IMAGING STUDY IN PATIENTS RECEIVING WBRT +/- SORAFENIB

BACKGROUND: Sorafenib has demonstrated anti-tumor efficacy in breast cancer and radiosensitizing activity preclinically. [18F] 3’deoxy-3’-fluorothymidine (FLT) is a PET tracer which correlates with cellular proliferation and may improve response assessment. METHODS: A phase I trial of whole brain ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morikawa, Aki, Grkovski, Milan, Patil, Sujata, Jhaveri, Komal, Tang, Kendrick, Humm, John, Holodny, Andrei, Beal, Kathryn, Schoder, Heiko, Seidman, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213141/ http://dx.doi.org/10.1093/noajnl/vdz014.061

Ejemplares similares

Efficacy and safety of WBRT+EGFR‐TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: An updated meta‐analysis
por: Zhou, Kai, et al.
Publicado: (2021)

Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis
por: Lu, Fei, et al.
Publicado: (2019)

Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life
por: Addeo, Raffaele, et al.
Publicado: (2007)

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan
por: Lo, Serigne N., et al.
Publicado: (2019)

RADI-01. PROGNOSTIC FACTORS OF SHORT SURVIVAL FOR BRAIN METASTASES TREATED WITH SRS WITHOUT WBRT.
por: Harat, Maciej, et al.
Publicado: (2019)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Setup uncertainties and appropriate setup margins in the head-tilted supine position of whole-brain radiotherapy (WBRT)
por: Park, Jae Won, et al.
Publicado: (2022)

WBRT vs. APBI: an interim report of patient satisfaction and outcomes
por: Bitter, Samantha M., et al.
Publicado: (2016)

Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study
por: Zhen, Junjie, et al.
Publicado: (2020)

WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view
por: Sas-Korczynska, Beata, et al.
Publicado: (2021)

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt
por: Gupta, Avinash, et al.
Publicado: (2016)

Reduced-dose WBRT combined with SRS for 1–4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control
por: Nakano, Toshimichi, et al.
Publicado: (2022)

Static beam tomotherapy as an optimisation method in whole‐breast radiation therapy (WBRT)
por: Squires, Matthew, et al.
Publicado: (2017)

RADI-16. Efficacy of WBRT among the Sub-types of Metastatic Breast Cancer
por: Mathew, Shija, et al.
Publicado: (2021)

Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC
por: Ren, Yue, et al.
Publicado: (2021)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

Comparison between flattening filter‐free (FFF) and flattened photon beam VMAT plans for the whole brain radiotherapy (WBRT) with hippocampus sparing
por: Ji, Tianlong, et al.
Publicado: (2021)

Assessment of multi‐criteria optimization (MCO) for volumetric modulated arc therapy (VMAT) in hippocampal avoidance whole brain radiation therapy (HA‐WBRT)
por: Zieminski, Stephen, et al.
Publicado: (2018)

Are hypothalamic- pituitary (HP) axis deficiencies after whole brain radiotherapy (WBRT) of relevance for adult cancer patients? – a systematic review of the literature
por: Mehta, P., et al.
Publicado: (2019)

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
por: Lesueur, Paul, et al.
Publicado: (2022)

Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis
por: Li, Zhensheng, et al.
Publicado: (2019)

Best Supportive Care Versus Whole-Brain Irradiation, Chemotherapy Alone, or WBRT Plus Chemotherapy in Patients With Brain Metastases From Small-Cell Lung Cancer: A Case-Controlled Analysis
por: Li, Hongwei, et al.
Publicado: (2021)

The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
por: de Pádua Covas Lage, Luís Alberto, et al.
Publicado: (2022)

Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol
por: Chia, Brendan Seng Hup, et al.
Publicado: (2020)

Use of a head-tilting baseplate during volumetric-modulated arc therapy (VMAT) to better protect organs at risk in hippocampal sparing whole brain radiotherapy (HS-WBRT)
por: Oh, Se An, et al.
Publicado: (2020)

RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM)
por: Tomé, Wolfgang, et al.
Publicado: (2019)

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer
por: Cai, Ling, et al.
Publicado: (2014)

The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood–Brain Barrier in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

MLTI-05. Adjuvant re-irradiation improves local control of surgically resected recurrent brain metastases
por: Wilcox, Jessica, et al.
Publicado: (2021)

MLTI-03. The relevance of the count of brain metastases for treatment and outcome in NSCLC
por: Reinecke, David, et al.
Publicado: (2021)

MLTI-04. The Role of the Outpatient Registered Nurse in the care of Brain Metastases
por: Hernandez, Juliana, et al.
Publicado: (2021)

RADI-04. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933
por: Bovi, Joseph, et al.
Publicado: (2019)

SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING
por: Pina, Yolanda, et al.
Publicado: (2023)

MLTI-19. VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH BRAIN METASTASES: THE PICOS SCORE
por: Wolpert, Fabian, et al.
Publicado: (2019)

MLTI-02. Impact of driver mutations on timing, pattern, treatment, and outcome in patients with brain metastases from non-small cell lung cancer
por: Jünger, Stephanie, et al.
Publicado: (2021)

MLTI-09. UNDERWEIGHT AND WEIGHT LOSS ARE PREDICTORS OF POOR OUTCOME IN PATIENTS WITH BRAIN METASTASIS
por: Weller, Michael, et al.
Publicado: (2019)

MLTI-06. BEVACIZUMAB VERSUS SURGICAL INTERVENTION FOR RADIATION NECROSIS IN PREVIOUSLY IRRADIATED BRAIN METASTASES
por: Hong, Christopher, et al.
Publicado: (2019)

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
por: Moreira, Raphael Brandão, et al.
Publicado: (2015)

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship
por: Liu, Tao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l0vuuigvthgt6eqfjedgv6oiq2